CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

pertuzumab

Last Updated: May 3, 2021
Result type: Reports
Project Number: PC0241-000
Product Line: Reimbursement Review

Generic Name: pertuzumab

Brand Name: Perjeta

Manufacturer: Hoffmann-La Roche Limited

Therapeutic Area: Early stage breast cancer

Indications: Perjeta in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either 2 cm in diameter or node positive).

Manufacturer Requested Reimbursement Criteria1: Pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either 2 cm in diameter or node positive). Patients should receive neoadjuvant treatment with pertuzumab in combination with trastuzumab and chemotherapy for three to six cycles depending on the regimen chosen. Patients who start pertuzumab in combination with trastuzumab and chemotherapy in the neoadjuvant setting and do not have residual disease following surgery should continue to receive adjuvant trastuzumab to complete one year of HER2-directed therapy.

Submission Type: Initial

Tumour Type: Breast

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule1: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openMarch 16, 2021
Call for patient/clinician input closedMay 07, 2021
Submission receivedApril 14, 2021
Submission acceptedApril 28, 2021
Review initiatedApril 29, 2021
Draft CADTH review report(s) provided to sponsor for commentJuly 14, 2021
Deadline for sponsors commentsJuly 23, 2021
CADTH responses on draft review report(s) provided to sponsorAugust 26, 2021
Expert committee meeting (initial)September 08, 2021
Draft recommendation issued to sponsorSeptember 20, 2021
To
September 22, 2021
Draft recommendation posted for stakeholder feedback-
Submit Feedback